Elk River Wealth Management LLC Sells 2,200 Shares of Pfizer Inc. (NYSE:PFE)

Elk River Wealth Management LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,872 shares of the biopharmaceutical company’s stock after selling 2,200 shares during the quarter. Elk River Wealth Management LLC’s holdings in Pfizer were worth $501,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. Cumberland Partners Ltd bought a new position in Pfizer during the fourth quarter worth $2,032,000. Ieq Capital LLC lifted its stake in shares of Pfizer by 14.3% during the 4th quarter. Ieq Capital LLC now owns 320,472 shares of the biopharmaceutical company’s stock worth $8,502,000 after buying an additional 40,117 shares during the last quarter. Emerald Advisors LLC boosted its holdings in shares of Pfizer by 8.3% during the 4th quarter. Emerald Advisors LLC now owns 28,474 shares of the biopharmaceutical company’s stock worth $755,000 after buying an additional 2,190 shares during the period. Private Wealth Partners LLC grew its stake in Pfizer by 29.6% in the 4th quarter. Private Wealth Partners LLC now owns 579,849 shares of the biopharmaceutical company’s stock valued at $15,383,000 after buying an additional 132,312 shares during the last quarter. Finally, Good Life Advisors LLC raised its holdings in Pfizer by 27.1% in the 4th quarter. Good Life Advisors LLC now owns 71,410 shares of the biopharmaceutical company’s stock valued at $1,895,000 after acquiring an additional 15,211 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $25.87 on Thursday. The firm’s 50 day simple moving average is $26.28 and its 200 day simple moving average is $27.45. The firm has a market capitalization of $146.58 billion, a price-to-earnings ratio of 18.34, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. The company’s revenue was up 24.7% compared to the same quarter last year. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.65%. Pfizer’s payout ratio is presently 121.99%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim restated a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.